Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Clover Biopharmaceuticals Ltd. ( (HK:2197) ).
Clover Biopharmaceuticals has granted 10,195,500 share options and 8,965,000 restricted share units to 43 eligible participants under its post-IPO share option plan and RSU scheme as of March 27, 2026. The options, priced at HK$2.84 per share with a 10-year validity, feature structured vesting schedules for employees and directors tied to both group-level metrics, such as R&D and financial performance, and individual performance targets, underscoring the company’s use of equity incentives to align management and staff with its strategic and operational goals.
The employee options will vest over four years, with 25% vesting after the first year and the remainder in three equal annual instalments, while all options granted to non-executive and independent non-executive directors will fully vest on the first anniversary. By linking vesting to key performance indicators, including progress of research and development programs and overall financial conditions, Clover aims to incentivize value creation, support talent retention, and reinforce its long-term development trajectory for shareholders and other stakeholders.
The most recent analyst rating on (HK:2197) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals, Ltd. is a biopharmaceutical company listed on the Hong Kong Stock Exchange that develops innovative biologic therapies. The company focuses on advancing its research and development pipeline and strengthening its financial position to enhance long-term growth and competitiveness in the global healthcare market.
Average Trading Volume: 4,201,445
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.57B
Find detailed analytics on 2197 stock on TipRanks’ Stock Analysis page.